suzetrigine (Journavx)
Jump to navigation
Jump to search
Indications
- non-opioid analgesic for acute pain (FDA-approved Jan 2025)
Contraindications
- strong CYP3A4 inhibitors
- avoid grapefruit
Dosage
- starter dose: 100 mg, then 50 mg every 12 hours
Adverse effects
- pruritus, rash
- muscle spasms
- increased serum creatine phosphokinase
Mechanism of action
- suzetrigine works by preventing pain-signaling nerves from firing in the first place
- closes sodium channel that conducts only pain signals
More general terms
References
- ↑ Goodman B FDA approves first new type of pain medication in 25 years. CNN Health. January 30, 2025 https://www.cnn.com/2025/01/30/health/fda-approves-painkiller-suzetrigine-journavx/index.html
George J FDA Approves Novel Pain Pill Without Addiction Risk. First-in-class non-opioid analgesic gets green light for acute pain. MedPage Today January 31, 2025 https://www.medpagetoday.com/painmanagement/painmanagement/114021
Dolgin E US drug agency approves potent painkiller - the first non-opioid in decades. Nature News. Jan 31, 2025 https://www.nature.com/articles/d41586-025-00274-1